Scribe Therapeutics Files for Nasdaq IPO

Scribe Therapeutics, a biotechnology company, has filed for an initial public offering (IPO) on the Nasdaq Global Market, revealing its intent to go public under the ticker symbol "SCTX." The company has submitted a registration statement but has not yet disclosed the number of shares to be offered or the expected price range, with placeholder values listed in the filing. Currently, no public market exists for Scribe's common stock, and the closing of the offering is contingent upon the company meeting Nasdaq's listing standards.

Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, and Wells Fargo Securities are serving as underwriters.

You May Also Be Interested In

• Tailored Brands files for IPO on Nasdaq
• Men’s Wearhouse owner Tailored Brands, bankrupt in 2020, files for IPO
• Niagen Bioscience files to sell up to $50M in common stock